Page 9 - Human Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

I hope they target those that are most likely to wenbenefit f the additional dose. >> if you are 50 and over, if you have a pre-existing condition, you can be eligible. as you point out, younger people are not. if it is authorized, pfizer would be authorized for 12 and up, as you point out. moderna, 18 and up. why not get it? if it's a smaller benefit, is there any reason not to get the booster? >> we're not going to have clinical studies before the launch. you would like to have human data. people getting the vaccine. you see a clear evidence of protection against ba.4 and ba.5. if there's no...

Advisor, expressed concerns about using the flu shot comparison. when we look at this, though, two-part question. one, based on what you know so far, does it appear that this booster, which is specifically targeting omicron, is going to be effective? >> well, that's the big question, right? and likely yes, but you'd certainly like to have some human data, something beyond mouse data to justify that. the thing is ba.5 is starting to go down now, and i think the thinking from the fda is that if we're going to immunize against ba.5, now is the time to do it. also as we move later into the fall, i...

As we see more data, because right now we have, again, a press release that the updated vaccine generated a good antibody response in animals. we don't have human data yet. so now to the first part, this is great. we want to see that. and the fda has already said they're not going to require lengthy clinical trials with their updated vaccines. think about flu every year. we change to adapt new strains. i'm not concerned about its safety or efficacy. we just don't have that solid data yet. but if you potentially is a candidate for a booster, talk to your doc and see if you should wait or get it...

17.08.2022 - Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced the U.S. Food and Drug Administration (FDA) has approved the citrate-free, high-concentration (100 mg/mL) formulation of HADLIMA (adalimumab-bwwd), a biosimilar referencing ...

He couldn't talk well or swallow, very painful. this seems to really help. a quick note, though, when you look at these types of medications, it was originally approved for smallpox, to really know how effective something is, you have to test it in the middle of an outbreak. there obviously hasn't been a smallpox outbreak in 50 years or longer than that. most of the data really comes from primates. you're now starting to get human data because of how large this monkeypox outbreak is. and so far encouraging in terms of how effective it is. >> yeah. encouraging how effective it is, but how readi...